マサチューセッツ州における非小細胞肺癌の臨床試験
マサチューセッツ州内の拠点で、非小細胞肺癌に関する102件の研究が参加者を募集しています。
マサチューセッツ州内の都市
- Boston90件の研究
- Worcester14件の研究
- Somerville6件の研究
- Newton5件の研究
- Lynn4件の研究
- Springfield4件の研究
- Lawrence3件の研究
- Quincy3件の研究
公式研究テキスト（英語）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Beverly Hospital, Beverly
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- 他8件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Massachusetts General Hospital ( Site 0136), Boston
- Dana Farber Cancer Hospital ( Site 0155), Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06623422Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- University of Massachusetts Memorial Medical Center, Worcester
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06472245The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07751042Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #7, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07090499Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06625775Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Beverly Hospital, Beverly
- Lahey Clinic, Burlington
- Addison Gilbert Hospital, Gloucester
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Local Institution - 0603, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07361497Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Dana-Farber Cancer Institute, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06765109A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Boston
- Research Site, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05877599Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Dana-Farber Cancer Institute /ID# 278417, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06772623A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07578571A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07127874A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- University of Massachusetts Worcester, Worcester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07144280A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Boston Medical Center, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05498428A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Reliant Medical Group Inc, Worcester
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/09/25更新 · NCT05920356Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06218914This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Southcoast Centers for Cancer Care, Fairhaven
- Southcoast Centers for Cancer Care, Fall River
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06758401A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Boston University Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667076A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667908Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Lahey Hospital & Medical Center, Burlington
- Reliant Medical Group, Worcester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06890598Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Massachusetts General Hospital Cancer Center, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT03191149Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Boston
- Research Site, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06357533Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Boston
被験者募集中第2相
18歳〜95歳 · 全性別 · 2026/09/23更新 · NCT05061550Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Dana-Farber Cancer Institute, Boston
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07100080A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Local Institution - 0019, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06875310Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Massachusetts General Hospital - Main Campus, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07629960Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Boston
- Clinical Study Site, Brighton
- Clinical Study Site, Foxborough
- 他4件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06767514A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06855771Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07349537Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Dana-Farber Cancer Institute, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07195695Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05786924Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute at St. Elizabeths Medical Center, Brighton
- Brigham and Womens/Mass General Health Care Center at Foxborough, Foxborough
- 他3件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT04613596Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Dana-Farber Cancer Institute, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06899126ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。